WO1986004599A1 - Process for producing foaming composition - Google Patents
Process for producing foaming composition Download PDFInfo
- Publication number
- WO1986004599A1 WO1986004599A1 PCT/JP1985/000050 JP8500050W WO8604599A1 WO 1986004599 A1 WO1986004599 A1 WO 1986004599A1 JP 8500050 W JP8500050 W JP 8500050W WO 8604599 A1 WO8604599 A1 WO 8604599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- component
- acid
- powder
- mixed
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title abstract description 25
- 238000005187 foaming Methods 0.000 title abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000006260 foam Substances 0.000 claims description 11
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 abstract description 15
- 229910000288 alkali metal carbonate Inorganic materials 0.000 abstract description 4
- 150000008041 alkali metal carbonates Chemical class 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 68
- 239000000843 powder Substances 0.000 description 38
- 239000003826 tablet Substances 0.000 description 37
- 239000008187 granular material Substances 0.000 description 35
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 34
- 235000017557 sodium bicarbonate Nutrition 0.000 description 34
- -1 carbonate compound Chemical class 0.000 description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 239000007938 effervescent tablet Substances 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 16
- 239000004299 sodium benzoate Substances 0.000 description 16
- 235000010234 sodium benzoate Nutrition 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 239000000314 lubricant Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000003765 sweetening agent Chemical class 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 229960003438 aspartame Drugs 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000011363 dried mixture Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000575 pesticide Substances 0.000 description 5
- 229940085605 saccharin sodium Drugs 0.000 description 5
- 239000000273 veterinary drug Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000011496 sports drink Nutrition 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000019987 cider Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000532467 Aletes Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 239000004135 Bone phosphate Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 229960000943 tartrazine Drugs 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000005980 Gibberellic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101100361772 Mus musculus Rptn gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VDNXILQBKLFION-UHFFFAOYSA-N [K].[Cu] Chemical compound [K].[Cu] VDNXILQBKLFION-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 239000002967 calcium-L-ascorbate Substances 0.000 description 1
- 235000005937 calcium-L-ascorbate Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- XJCRCPKBJWRZAX-UHFFFAOYSA-L disodium;dibenzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 XJCRCPKBJWRZAX-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940087379 sodium bicarbonate 500 mg Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013522 vodka Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/16—Foams
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/40—Effervescence-generating compositions
Definitions
- the present invention relates to a foaming composition having excellent properties of breaking down and foaming in a short time.
- the powder of the base component (carbonic acid compound) and the powder of the acid component are separately humidified with water, combined, dried, and then dried.
- the company manufactures effervescent tablets by adding tablets and pharmaceutical ingredients.
- the particles after humidification become fine, and the ratio of the powder in the whole becomes large because the pharmaceutical ingredient is added after humidification and drying.
- the proportion of the powder is too large (40% or more), the fluidity becomes poor, and tableting may not be possible because the mixed powder does not flow from the hopper of the tableting machine.
- a carbonate compound, an acid compound and a pharmaceutical ingredient are mixed, granulated, humidified, dried, and then tableted. Manufactures effervescent tablets.
- the present inventors have conducted intensive studies on a method for producing a foamed composition that foams quickly and quickly, and that is easy to produce, and found that one or both of a carbonate compound component and an acid compound component It has been found that a foamed composition satisfying the above-mentioned purpose can be produced by mixing the active ingredients in a mixture, humidifying each with about 0.5 to 5% of water, and then mixing. As a result of research, the present invention has been completed.
- the present invention provides a solid alkali metal carbonate (A component) (hereinafter sometimes referred to as an alkali component) and a solid aliphatic carboxylic acid (B component) (hereinafter sometimes referred to as an acid component). And the active component (C component) is blended to produce a foamed composition, wherein the C component is mixed with one or both of the A component and the B component, and each of them is added to about 0.5 to 5% (wZw).
- a component solid alkali metal carbonate
- B component solid aliphatic carboxylic acid
- C component active component
- This is a method for producing a foaming composition containing an active ingredient, which comprises mixing after humidification with water.
- alkali metal salt of carbonic acid used in the present invention examples include alkali metal carbonate, alkali metal bicarbonate, and earth metal carbonate. I can do it. .
- alkali metal examples include sodium and potassium
- examples of the alkaline earth metal examples include potassium and magnesium.
- metal salt of carbonic acid examples include sodium carbonate and carbonated carbonate, with sodium carbonate being most preferred.
- alkali metal bicarbonate include sodium bicarbonate and sodium bicarbonate, with sodium bicarbonate being preferred.
- alkali earth metal salt include, for example, calcium carbonate, magnesium carbonate, barium carbonate and the like, and among them, calcium carbonate is preferable.
- the metal salt of carbonic acid used in the present invention may be a mixture of the above compounds.
- the alkali metal salt of carbonic acid is used in a solid state. Examples of the solid form include a powder form and a granular form, and among them, a granular form is preferable.
- the aliphatic carboxylic acids used in the present invention include monobasic, dibasic and tribasic.
- Examples of the basic aliphatic carboxylic acid include glacial acetic acid and dalicholic acid.
- Examples of the dibasic aliphatic carboxylic acid include tartaric acid, phthalic acid, maleic acid, malonic acid, lingic acid, and succinic acid.
- Examples of the tribasic aliphatic carboxylic acid include citric anhydride, citric acid, isocunic acid and the like.
- the aliphatic carboxylic acid may be a mixture of the above compounds.
- citrate anhydride is most preferred.
- solid aliphatic carboxylic acids examples include powdery carboxylic acids and granules In particular, granular ones are preferred.
- the ratio of the component A to the component B is preferably about 1: 1 to 1: 2 (w / w).
- Examples of the active ingredient of the present invention include pharmaceuticals, foods, agricultural chemicals, veterinary drugs, and the like.
- the drug examples include vitamin C (L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate), paraacetamol (acetaminophene), aspirin (acetylsalicylic acid), or a mixture thereof.
- the combination of al or total vitamin component eg, vitamin a, B t, B 2, B 3, B 5, B 8, B 12, C, D, E, folic acid, Mi Neraru (e.g., iron, Calcium, copper potassium, magnesium, manganese, zinc, oxide) etc.
- the amount is about 40% based on the foaming ingredient (A ingredient and B ingredient). % (Weight) or less is preferred.
- Such foods include powdered liquor, aspartame (—L-aspartyl—L-phenylalanine methyl ester), acesulfame [6-methyl-1,1,2,3, oxatiazine-1-4- (3 ⁇ ) -one-one 2,2 dioxan] or its salts, such as metal salts of alkali metal, sweeteners such as sarin phosphorus, sugar, etc., vitamin and mineral mixtures such as sports drinks, and teas containing herbal extracts. And the like.
- the amount is preferably about 60% (weight) or less based on the foaming ingredients ( ⁇ and ⁇ ).
- pesticides examples include gibberellic acid.
- the amount is preferably about 60% (weight) or less based on the foaming ingredients ( ⁇ and ⁇ ).
- veterinary drug examples include ditroflazone.sulfadimethoxine, furazolidone, chlortetracycline and the like.
- the amount is preferably about 60% (weight) or less based on the foaming ingredients (A and B components).
- the active ingredient of the present invention may be in the form of powder or granulated. Among them, granulated ones are preferred.
- the basic active ingredient is mixed with an alkali metal carbonate (A component).
- the acidic active ingredient is preferably mixed with an aliphatic carboxylic acid (component B).
- the neutral active ingredient may be mixed with either component A or component B, or one of them.
- Examples of the shape of the composition of the present invention include tablets and granules.
- the method for producing the foam composition of the present invention is described below.
- the active ingredient is mixed with the alkali metal salt of carbonic acid (component A) if necessary, and further the binder is mixed if necessary.
- the mixture is humidified with about 0.5 to 5% (w / w) water.
- the binder include polyvinylpyrrolidone, dextrin, dextrose, milk, arabia gum powder, methylcellulose, hydr, mouth xip ⁇ -pyrmethylcellulose, and the like.
- the amount of water used is preferably about 1 to 3% (w / w), more preferably about 1 to 2% (w /).
- the water may be added with an organic solvent if desired.
- the organic solvent include ethanol, acetone, etc.
- the ratio of water to the organic solvent is preferably about 1: 1 to 1: 4 (v / v).
- a coloring agent such as riboflavin, and synthetic coloring agents such as tartrazine and Sanse's yellow.
- the sweetener include saccharin, aspartame, sugar and the like.
- the active ingredient is mixed with the solid aliphatic carboxylic acid (component B) if necessary. Further, the binder is mixed if necessary, and the mixture is humidified with about 0.5 to 5% (w / w) water.
- binder examples include those similar to those used in the humidification step of the component A described above.
- the amount of water used is more preferably about 1 to 3% (wZw), more preferably about 1 to 2% (w / w).
- water to which an organic solvent is added as required may be used.
- organic solvent and the amount thereof used are the same as those used in the humidification step of the component A, and the same amount used.
- a granular product is obtained.
- the granules thus obtained are subjected to the next step.
- the granules are further passed through an 8 mesh (JIS standard) sieve, and are then passed through a 100 mesh (JIS standard) screen. It is preferably of a size that does not pass through a sieve of (Standard).
- the granules thus obtained are subjected to a drying step.
- the drying method includes, for example, drying in a vacuum dryer at about 40 ° C. to 60 ° C., about 0 to 5 mmHg, for about 8 to 16 hours, and about 40 to 6 hours in a ventilation dryer. Drying at 0 ° C for about 1 to 3 hours.
- a lubricant prepared by dispersing a lubricant may be added to the foamed granules containing an acid component and an alcohol component. This is because when the lubricant is mixed with foamed granules as they are, they tend to become spherical large granules due to static electricity. Therefore, by mixing a lubricant with, for example, an alkali component or an acid component and sieving, it is possible to prevent the lubricant from being granulated and to improve the effect of the lubricant, thereby facilitating tableting. Can do it.
- the foaming power of the obtained tablet can be enhanced by adding a separately granulated carbonic acid metal salt.
- the granules are compressed.
- a coloring agent, a flavor, a sweetener, a seasoning, a binder, a compression-contraction lubricant, and the like may be added to the granules, if desired, and then the tableting step may be performed.
- coloring agent examples include riboflavin, tartrazine, sanse, soto yellow and the like.
- flavor examples include orange oil, lemon oil, orange powder, lemon powder and the like.
- sweetener examples include saccharin, aspartame, sugar and the like.
- seasoning examples include sodium glutamate, nucleic acid seasoning, succinic acid, and powder * katsudashi.
- a tablet may be prepared by adding an emulsifier or the like, for example.
- the emulsifier include sodium lauryl sulfate, polyvinylpyrrolidone, polyethylene glycol, fatty acid ester of polyhydric alcohol such as span (sorbitan fatty acid ester, manufactured by Atlas Powder Co., USA) ), Sugars (fatty acid esters of polyoxyethylene sorbitan, manufactured by Atlas Powder Co.), sugar esters, and the like.
- an emulsifier and the like may be added to make a tablet.
- the emulsifier include sodium lauryl sulfate, polyvinylpyrrolidone, polyethylene glycol, and fatty acid esters of polyhydric alcohols, such as spun, tween, and sugar esters.
- the binder used for tableting include polyvinyl pyrrolide. Dextrin, arabia gum powder, methylcellulose, hydroxy ⁇ -pyrmethylcellulose, and sugar.
- compression lubricants used for tableting include sodium stearate, sodium benzoate, polyethylene glycol 400, polyethylene glycol 600, and the like.
- Tableting is performed by a commonly used method known per se.
- a composition containing an effective amount of the medicament is administered to a human, for example, as follows.
- Oral administration by swallowing after dissolving or suspending in the mouth is possible.
- a solution or suspension is prepared by foaming in water and applied to the skin to administer the drug transdermally.
- the drug is absorbed by effervescent dissolution or suspension by intravaginal administration: Specifically, for example, the effervescent tablet of the present invention containing about 500 to 100 mg of ascorbic acid per tablet Put 1-2 tablets in about 60-200 ml of water to dissolve and foam.
- a composition containing an amount of the food to be an effective intake is used, for example, as follows.
- 1 to 2 effervescent tablets of the present invention containing about 500 to 100 mg of tea containing a crude drug extract in i tablets at 40 ° C. to 80 ° C. 60 ⁇ 10 Om U squeeze foam to dissolve and drink this.
- a composition containing an effective amount of the pesticide to be sprayed is, for example, the composition is foamed in water to form a solution or a suspension. Spray on living things.
- a composition containing an effective amount of the animal drug is administered, for example, as follows.
- the object foaming composition of the present invention is a granule
- the granule has a small amount of fine powder and a uniform particle size, so that it is easy to be strip-packaged, and the fine powder is applied to the film bonding portion of the strip package. There is no such thing as causing poor adhesion due to sticking. Therefore, the granules are easy to handle.
- the granules are large uniform granules, and when poured into water, foam well after sinking to the bottom.
- the foamed composition when the foamed composition is in the form of granules, drying is easy because a small amount of water is used. Also, if the moistened acid component and alkali component are mixed, uniform granules can be formed without being hardened largely, so that the granulation step before the drying step, which is required for the usual granule manufacturing process, can be omitted. it can. Furthermore, after the granules are dried, It is not sized and can be easily sized by sieving. Therefore, industrial production of the granules is easy.
- the acid component and the alcohol component must be separately kneaded, granulated, and dried in the conventional production of effervescent tablets.
- kneading, granulation, drying and granulation can be carried out after mixing the acid component and the alkali component, so that the number of production steps can be reduced.
- the granules obtained by the method of the present invention have a small amount of fine powder, a small amount of lubricant is required at the time of tablet production, and the tableting property is good. Further, since the granules have a small amount of fine powder, it is possible to prevent sticking and sticking during tableting.
- the disintegrant when the composition is a tablet, the disintegrant is required for an effervescent tablet that has a long disintegration time in water and is long submerged in water. Has properties. .
- the hardness of the tablet can be adjusted to about 2 to 15 kg.
- the decay time becomes slower as the hardness increases, so the decay time can be adjusted according to the application.
- the foaming state of the tablet can be adjusted.
- the hardness is set to 2 to 4 kg, a large amount of fine bubbles are generated and collapse within 1 minute.
- the hardness is set to 5 kg or more, the foam increases and the crushing time becomes 1 minute or more.
- 10 tablets of vitamin C-containing effervescent tablets obtained by the method of the present invention were screw-capped together with a silylation gel and stored at 60 ° C for 1 month. Since there is no significant change in the foaming time and content, the foamed tablet containing vitamin C obtained by the method of the present invention is considered to be stable at room temperature for at least 2 to 3 years.
- vitamin 0 has the property of easily discoloring and is unstable to ripening and moisture, but is stable in the tablet.
- An effervescent tablet having the following formulation A composition was prepared.
- the obtained mixture was dried in a vacuum drier at 40 to 0.5 ⁇ 113 for 16 hours to produce expanded granules.
- the resulting colored and moistened sodium bicarbonate was dried in a vacuum drier at 40 ° C. and 5 mmHg for 16 hours to produce colored sodium bicarbonate.
- Example 2 The diameter, thickness, weight and hardness of the effervescent tablet obtained in this way, the effervescence time, efflux state, PH and taste when the tablet is dissolved in 100 ml of water at 24 ° C under normal pressure are shown below.
- Example 2 The diameter, thickness, weight and hardness of the effervescent tablet obtained in this way, the effervescence time, efflux state, PH and taste when the tablet is dissolved in 100 ml of water at 24 ° C under normal pressure are shown below.
- Example 2 The diameter, thickness, weight and hardness of the effervescent tablet obtained in this way, the effervescence time, efflux state, PH and taste when the tablet is dissolved in 100 ml of water at 24 ° C under normal pressure are shown below.
- Example 2 The diameter, thickness, weight and hardness of the effervescent tablet obtained in this way, the effervescence time, efflux state, PH and taste when the tablet is dissolved in 100 ml of water
- the obtained mixture was dried in a vacuum dryer at 40 ° C. and 5 Hg for 16 hours to produce expanded granules.
- the obtained colored and moistened sodium bicarbonate was dried in a vacuum drier at 40 ° C. and 5 mmHg for 16 hours to produce colored sodium bicarbonate.
- the rotation speed of the tableting machine was set at 14 revolutions / minute, and the mixture obtained in the above (3) was tableted using a 15 mm-diameter corner round punch.
- the diameter, thickness, weight and hardness of the effervescent tablet thus obtained, the effervescence time when the tablet is dissolved in 10 Oml of water at 24 ° C under normal pressure, effervescent state, pH, taste, diameter, thickness and The weight is shown below.
- the obtained mixture was dried in a vacuum drier at 40, 5 with 118 for 16 hours to produce expanded granules.
- the obtained colored and humidified sodium bicarbonate was dried in a vacuum dryer at 40 ° C. and 5 Hg for 16 hours to produce colored sodium bicarbonate.
- the diameter, thickness, weight, and hardness of the effervescent tablet thus obtained, and the foaming time, foaming state, pH, and taste when the tablet is dissolved in 100 ml of water at 24 ° C under normal pressure are as follows. Show.
- An effervescent tablet having the following formulation E composition was prepared.
- the foaming time when dissolved in 100 ml under normal pressure was 37 seconds.
- Sports drinks Vitamin ⁇ Mineral mixed soft drink. The following vitamins in 13 g of sports drinks ⁇ Contains minerals.
- composition of the present invention can be used as a pharmaceutical composition, a food composition, a pesticide composition, and a veterinary drug composition, which quickly disintegrates and rapidly foams.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Food Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
A process for producing a foaming composition showing a short disintegration time by compounding a solid alkali metal carbonate (ingredient A), a solid aliphatic carboxylic acid (ingredient B), and an active ingredient (ingredient C), wherein ingredient C is mixed with one or both of ingredients A and B, and each of the resulting mixture is moistened with about 0.5 to about 5 wt % water and mixed with each other.
Description
明 細 書 Specification
発泡組成物の製造法 Method for producing foam composition
技術分野 Technical field
本発明は、 短時間で崩壌,発泡する優れた性質を有する発泡組成物 関する。 The present invention relates to a foaming composition having excellent properties of breaking down and foaming in a short time.
背景技術 Background art
発泡組成物の製造法としては、 種々知られているが、 なかでも、 フラ ンス特許第 6 9 . 1 5 3 6 0号(公開番号第 2 , 0 4 4 , 2 1 6号)および 米国特許第 3 , 7 7 3 , 9 2 2号公報が挙げられ、 これらにおいては、 少 量の水を用いて発泡成分である炭酸化合物と酸化合物を加湿し、 最終的 に錠剤を得ている。 ' There are various known methods for producing a foamed composition. Among them, French Patent No. 69.1530 (publication number 2,044, 216) and US Patent No. 3,773,922 are mentioned, in which a small amount of water is used to humidify a carbonate compound and an acid compound as foaming components to finally obtain tablets. '
上記フランス特許第 6 9 . 1 5 3 6 0号の方法においては、 塩基成分 の粉末(炭酸化合物)と酸成分の粉.末とを別個に水で加湿し S合'し乾燥し. た後、 医薬成分を加え、 打錠し、 発泡錠を製造している。 In the method of the above-mentioned French Patent No. 69.15360, the powder of the base component (carbonic acid compound) and the powder of the acid component are separately humidified with water, combined, dried, and then dried. The company manufactures effervescent tablets by adding tablets and pharmaceutical ingredients.
しかしながら、 該フランス特許の方法では、 加湿後の粒子は微小なも のとなり、 また、 加湿乾燥後医薬成分を加えるので全体に占める粉末の 割合が多くなり、 打錠にあたっては、 ひっつき、 ぎしつき等打錠工程に おいて、 種々の不都合を生じる。 また、 あまり粉末の割合が多くなると ( 4 0 %以上)、 流動性が悪くなり、 打錠機のホッパーから混合粉末が流 れない為、 打錠不可能になる場合もある。 However, according to the method of the French patent, the particles after humidification become fine, and the ratio of the powder in the whole becomes large because the pharmaceutical ingredient is added after humidification and drying. In tableting, sticking, sticking, etc. Various inconveniences occur in the tableting process. On the other hand, if the proportion of the powder is too large (40% or more), the fluidity becomes poor, and tableting may not be possible because the mixed powder does not flow from the hopper of the tableting machine.
また、 上記米国特許第 3 , 7 7 3 , 9 2 2号公報に記載の方法において は、 炭酸化合物,酸化合物および医薬成分を混合し造粒した後加湿し、 その後乾燥しついで打錠し、 発泡錠を製造している。 Further, in the method described in the above-mentioned U.S. Pat. No. 3,773,922, a carbonate compound, an acid compound and a pharmaceutical ingredient are mixed, granulated, humidified, dried, and then tableted. Manufactures effervescent tablets.
しかしながら、 該米国特許の方法では、 重炭酸アルカリに対し 1 wt % 以下の水分を添加するものであるが、 加える医薬とクェン酸の量が重炭 酸アル力リの量を越えるとき、 全重量に対する添加水分の量はフランス
特許の 0 . 5 %以下の水分添加と同じになり、 上記に記した如く、 微小 な粒子しかできないので、 打錠にあたっては、 滑沢剤の効果が薄れ、 ひつ つき、 ぎしつきの原因となる。 酸とアルカリの混合物に対して色々の量 の水を蒸気化して造粒させているが特殊な装置が必要とされ一般的でな い。 又水蒸気による加湿は、 水の添加による加湿と比較し時間がかかり、 又吸湿量をコン トロールするのは困難である。 米国特許の実施例では重 炭酸ソーダを加湿後、 乾燥した無水クェン酸を注入しているが、 無水ク ェン酸が、 その加湿された重炭酸ソ一ダによって加湿されるまで無水ク ェン酸中での水分分布に差が出来ることによって生ずる反応が進んだと ころとそうでないところでは差があり、 均質な混合物が得られにく い。 発明の開示 However, in the method of the U.S. Patent, water of 1 wt% or less is added to the alkali bicarbonate, but when the amount of the added medicine and citric acid exceeds the amount of bicarbonate alcohol, the total weight is reduced. Of water added to France The effect is the same as adding 0.5% or less of water in the patent, and as described above, only fine particles can be formed. Therefore, in tableting, the effect of the lubricant is weakened, resulting in sticking and sticking. Various amounts of water are vaporized and granulated for a mixture of acid and alkali, but special equipment is required and this is not common. Also, humidification by water vapor takes longer time than humidification by addition of water, and it is difficult to control the amount of moisture absorption. In the example of the U.S. patent, dried sodium citrate is injected after humidification of sodium bicarbonate, but anhydrous citrate is added until the acid is humidified by the humidified sodium bicarbonate. It is difficult to obtain a homogeneous mixture because the reaction caused by the difference in the water distribution in the acid has progressed and the reaction has not proceeded. Disclosure of the invention
本発明者らは、 崩壌時間が早ぐ、 速かに発泡し、 しかも製造が容易な 発泡組成物を製造する方法につき、 鋭意研究したところ、 炭酸化合物成 分および酸化合物成分の一方あるいは両方に活性成分を混合し、 両者を それぞれ約 0 . 5ないし 5 %の水で加湿したのち混合する工程を経るこ とにより、 上記目的を満足する発泡組成物を製造することができること を見い出し、 さらに研究した锆果、 本発明を完成した。 The present inventors have conducted intensive studies on a method for producing a foamed composition that foams quickly and quickly, and that is easy to produce, and found that one or both of a carbonate compound component and an acid compound component It has been found that a foamed composition satisfying the above-mentioned purpose can be produced by mixing the active ingredients in a mixture, humidifying each with about 0.5 to 5% of water, and then mixing. As a result of research, the present invention has been completed.
本発明は、 固体状の炭酸のアルカリ金属塩(A成分)(以下、 アルカリ 成分ということもある。 ),固体状の脂肪族カルボン酸(B成分)(以下、 酸成分ということもある。 )および活性成分( C成分)を配合して発泡組 成物を製造する方法において、 A成分および B成分の一方あるいは両方 に C成分を混合し、 両者をそれぞれ約 0 . 5ないし 5 % (wZw)の水で加 湿したのち混合することを特徵とする活性成分含有発泡組成物の製造法 である。 The present invention provides a solid alkali metal carbonate (A component) (hereinafter sometimes referred to as an alkali component) and a solid aliphatic carboxylic acid (B component) (hereinafter sometimes referred to as an acid component). And the active component (C component) is blended to produce a foamed composition, wherein the C component is mixed with one or both of the A component and the B component, and each of them is added to about 0.5 to 5% (wZw). This is a method for producing a foaming composition containing an active ingredient, which comprises mixing after humidification with water.
本発明で用いられる炭酸のアル力リ金属塩としては、 たとえば炭酸ァ ルカリ金属塩,重炭酸アル力リ金属塩,炭酸アル力リ土類金属塩などが挙
げられる。 . Examples of the alkali metal salt of carbonic acid used in the present invention include alkali metal carbonate, alkali metal bicarbonate, and earth metal carbonate. I can do it. .
該アルカリ金属としては、 たとえばナトリ ウム,カリウムなどが、 該 アルカ リ土類金属としてはたとえば力ルシゥム,マグネシウムノくリ ゥ厶 などが、 それぞれ挙げられる。 Examples of the alkali metal include sodium and potassium, and examples of the alkaline earth metal include potassium and magnesium.
該炭酸のアル力リ金属塩の具体例としては、 たとえば炭酸ナトリゥム, 炭酸力リゥムなどが挙げられ、 なかでも炭酸ナトリ ゥムが最も好ましい。 該重炭酸アル力リ金属塩の具体例としては、 たとえば重炭酸ナトリウム, 重炭酸力リゥムなどが挙げられ、 なかでも重炭酸ナトリゥムが好ましい。 該ァルカリ土類金属塩の具体例としては、 たとえば炭酸カルシウム,炭 酸マグネシウム,炭酸バリウムなどが挙げられ、 なかでも炭酸力ルシゥ ムが好ましい。 Specific examples of the metal salt of carbonic acid include sodium carbonate and carbonated carbonate, with sodium carbonate being most preferred. Specific examples of the alkali metal bicarbonate include sodium bicarbonate and sodium bicarbonate, with sodium bicarbonate being preferred. Specific examples of the alkali earth metal salt include, for example, calcium carbonate, magnesium carbonate, barium carbonate and the like, and among them, calcium carbonate is preferable.
本発明で用いられる炭酸のアル力リ金属塩としては、 上記した化合物 の混合物でもよい。 · . 該炭酸のアルカリ金属塩は、 固体状のものが用いられる。 固体状とし ては、 たとえば粉末状,顆粒状が挙げられ、 なかでも、 顆粒状のものが 好ましい。 The metal salt of carbonic acid used in the present invention may be a mixture of the above compounds. · The alkali metal salt of carbonic acid is used in a solid state. Examples of the solid form include a powder form and a granular form, and among them, a granular form is preferable.
本発明で用いられる脂肪族カルボン酸としては、 一塩基性のもの、 二 塩基性のもの、 三塩基性のものなどが挙げられる。 The aliphatic carboxylic acids used in the present invention include monobasic, dibasic and tribasic.
該ー塩基性脂肪族カルボン酸としては、 たとえば氷酢酸,ダリ コール 酸などが挙げられる。 該ニ塩基性脂肪族カルボン酸としては、 たとえば 酒石酸,フタール酸,マレイン酸,マロン酸,リ ンゴ酸,コハク酸などが挙 げられる。 該三塩基性脂肪族カルボン酸としては、 たとえば無水クェン 酸,クェン酸,イソクェン酸などが挙げられる。 Examples of the basic aliphatic carboxylic acid include glacial acetic acid and dalicholic acid. Examples of the dibasic aliphatic carboxylic acid include tartaric acid, phthalic acid, maleic acid, malonic acid, lingic acid, and succinic acid. Examples of the tribasic aliphatic carboxylic acid include citric anhydride, citric acid, isocunic acid and the like.
脂肪族カルボン酸は、 上記した化合物の混合物でもよい。 脂肪族カル ボン酸としては、 なかでも無水クェン酸が最も好ましい。 The aliphatic carboxylic acid may be a mixture of the above compounds. Among the aliphatic carboxylic acids, citrate anhydride is most preferred.
該固体状の脂肪族カルボン酸としては、 たとえば粉末状のもの、 顆粒
状のものが挙げられ、 なかでも顆粒状のものが好ましい。 Examples of the solid aliphatic carboxylic acids include powdery carboxylic acids and granules In particular, granular ones are preferred.
上記 A成分と B成分との比は、 約 1対 1ないし 1対 2 (w/w)が好まし い。 The ratio of the component A to the component B is preferably about 1: 1 to 1: 2 (w / w).
本発明の活性成分としては、 たとえば医薬,食品,農薬,動物用薬など が挙げられる。 Examples of the active ingredient of the present invention include pharmaceuticals, foods, agricultural chemicals, veterinary drugs, and the like.
該医薬としては、 たとえばビタ ミ ン C (L—ァスコルビン酸, Lーァス コルビン酸ナトリウム, Lーァスコルビン酸カルシウム),パラァセタモ ール(ァセ トァミ ノ フェン),ァスピリ ン(ァセチルサリチル酸),またはこ れらの組み合わせ、 または総合ビタミ ン剤成分 [例、 ビタミ ン A,B t, B2,B3,B5,B8,B12, C,D ,E,葉酸, ミ ネラル(例、 鉄,カルシウム,銅 カリウム,マグネシウム,マンガン,亜鉛,ョ―ド)など]などが挙げられる < 医薬を活性成分として混合する場合の量としては、 発泡成分(A成分 および B成分)に対して約 4 0 % (重量)以下が好ましい。 Examples of the drug include vitamin C (L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate), paraacetamol (acetaminophene), aspirin (acetylsalicylic acid), or a mixture thereof. the combination of al or total vitamin component [eg, vitamin a, B t, B 2, B 3, B 5, B 8, B 12, C, D, E, folic acid, Mi Neraru (e.g., iron, Calcium, copper potassium, magnesium, manganese, zinc, oxide) etc. <When the drug is mixed as an active ingredient, the amount is about 40% based on the foaming ingredient (A ingredient and B ingredient). % (Weight) or less is preferred.
該食品としては、 たとえば粉末酒,アスパルテーム( — Lーァスパル チル— L一フエ二ルァラニンメチルエステル),アセスルファム [6—メ チル一 1 , 2 , 3—ォキサチアジン一 4— (3 Η)—オン一 2 , 2—ジォキ サン]又はその力リゥ厶などのアル力リ金属塩,サッ力リ ン,砂糖等の甘 味剤,スポーツ ドリ ンク等のビタ ミ ンおよびミネラル混合物,生薬抽出物 を含む茶などが挙げられる。 Examples of such foods include powdered liquor, aspartame (—L-aspartyl—L-phenylalanine methyl ester), acesulfame [6-methyl-1,1,2,3, oxatiazine-1-4- (3Η) -one-one 2,2 dioxan] or its salts, such as metal salts of alkali metal, sweeteners such as sarin phosphorus, sugar, etc., vitamin and mineral mixtures such as sports drinks, and teas containing herbal extracts. And the like.
食品を活性成分として混合する場合の量としては、 発泡成分(Α成分 および Β成分)に対して約 6 0 % (重量)以下が好ましい。 When the food is mixed as the active ingredient, the amount is preferably about 60% (weight) or less based on the foaming ingredients (成分 and Β).
該農薬としては、 たとえばジべレリ ン酸などが挙げられる。 Examples of the pesticides include gibberellic acid.
農薬を活性成分として混合する場合の量としては、 発泡成分(Α成分 および Β成分)に対し約 6 0 % (重量)以下が望ましい。 When the pesticide is mixed as an active ingredient, the amount is preferably about 60% (weight) or less based on the foaming ingredients (Α and Β).
該動物用薬としては、 たとえば二トロフラゾン.スルファジメ トキシ ン,フラゾリ ドン,クロルテ トラサイク リ ンなどが挙げられる。
動物用薬を活性成分として混合する場合の量としては、 発泡成分(A 成分および B成分)に対し約 6 0 % (重量)以下が望ましい。 Examples of the veterinary drug include ditroflazone.sulfadimethoxine, furazolidone, chlortetracycline and the like. When the veterinary drug is mixed as the active ingredient, the amount is preferably about 60% (weight) or less based on the foaming ingredients (A and B components).
本発明の活性成分は、 粉末状のものでも、 顆粒化されたものでもよい。 なかでも、 顆粒化されたものが好ましい。 The active ingredient of the present invention may be in the form of powder or granulated. Among them, granulated ones are preferred.
活性成分の混合については、 塩基性の活性成分は、 炭酸のアルカリ金 属塩(A成分)と混合するのが好ましい。 酸性の活性成分は、 脂肪族カル ボン酸(B成分)と混合するのが好ましい。 中性の活性成分は、 A成分お よび B成分のどちらに混合してもよいし、 一方でもよい。 As for the mixing of the active ingredients, it is preferable that the basic active ingredient is mixed with an alkali metal carbonate (A component). The acidic active ingredient is preferably mixed with an aliphatic carboxylic acid (component B). The neutral active ingredient may be mixed with either component A or component B, or one of them.
本発明の組成物の形状としては、 たとえば錠剤,顆粒剤などが挙げら れる。 Examples of the shape of the composition of the present invention include tablets and granules.
本発明の発泡組成物の製造法を以下に記載する。 炭酸のアル力リ金属 塩( A成分)に、 必要により活性成分を混合し、 さらに必要により結合剤 を混合し、 これを約 0 . 5ないし 5 % (w/w)の水で加湿する。 該結合 剤の例としては、 たとえばポリ ビニルピロリ ドン,デキストリ ン,デキス トロース,乳饍,ァラビアゴム末,メチルセルロース,ヒ ド、口キシプ σピル メチルセルロースなどが挙げられる。 The method for producing the foam composition of the present invention is described below. The active ingredient is mixed with the alkali metal salt of carbonic acid (component A) if necessary, and further the binder is mixed if necessary. The mixture is humidified with about 0.5 to 5% (w / w) water. Examples of the binder include polyvinylpyrrolidone, dextrin, dextrose, milk, arabia gum powder, methylcellulose, hydr, mouth xip σ-pyrmethylcellulose, and the like.
用いられる水の量としては、 さらに、 約 1 ないし 3 % (w/w)が、 さら に約 1 ないし 2 % (w / が好ましい。 該水は、 所望により有機溶媒を 添加したものを用いてもよい。 該有機溶媒としては、 たとえばエタノー ル,アセトンなどが挙げられる。 この場合、 水と有機溶媒との比率は、 約 1対 1 ないし 1対 4 (v/v)が好ましい。 The amount of water used is preferably about 1 to 3% (w / w), more preferably about 1 to 2% (w /). The water may be added with an organic solvent if desired. Examples of the organic solvent include ethanol, acetone, etc. In this case, the ratio of water to the organic solvent is preferably about 1: 1 to 1: 4 (v / v).
また、 該水に、 着色料,甘味料なども添加し、 溶液としておいてもよ い。 該着色料としては、 たとえば、 リボフラビン,合成着色料たとえば、 ター トラジン,サンセ 'ソ トイエローなどが挙げられる。 該甘味料として は、 たとえばサッカリ ン,アスパルテーム,砂糖などが挙げられる。 In addition, a coloring agent, a sweetener, and the like may be added to the water to form a solution. Examples of the coloring agent include riboflavin, and synthetic coloring agents such as tartrazine and Sanse's yellow. Examples of the sweetener include saccharin, aspartame, sugar and the like.
加湿する方法としては、 攪拌機中に入れ攪拌しながら水をスプレーす
る方法,攪拌機中に入れ攪拌しながら少量ずつ水を滴下させる方法など が挙げられる。 As a method of humidification, put in a stirrer and spray water while stirring. And a method of dropping water little by little while stirring in a stirrer.
固体状の脂肪族カルボン酸(B成分)に、 必要により活性成分を混合し. さらに必要により結合剤を混合し、 これを約 0 . 5ないし 5 % (w/w)の 水で加湿する。 The active ingredient is mixed with the solid aliphatic carboxylic acid (component B) if necessary. Further, the binder is mixed if necessary, and the mixture is humidified with about 0.5 to 5% (w / w) water.
該結合剤としては、 前記した A成分の加湿工程において用いられるも のと同様のものが挙げられる。 Examples of the binder include those similar to those used in the humidification step of the component A described above.
用いられる水の量としては、 さらに約 1 ないし 3 % (wZw)が、 さらに 約 1 ないし 2 % (w/w)が好ましい。 The amount of water used is more preferably about 1 to 3% (wZw), more preferably about 1 to 2% (w / w).
該水は、 所望により有機溶媒を添加したものを用いてもよい。 該有機 溶媒およびその使用量としては、 前記した A成分の加湿工程において用 いられるものと同様のもの,同様の使用量が挙げられる。 As the water, water to which an organic solvent is added as required may be used. Examples of the organic solvent and the amount thereof used are the same as those used in the humidification step of the component A, and the same amount used.
• A成分および B成分をそれぞれ別個に加湿した後、 これらを混合する c 混合する方法としては、 たとえばバーチカルグラ二ユレ一ター(富士産 業株式会社製,日本)等の攪拌機中で約 3〜 5分間混合する。 • After each separately humidify the A and B components, as a method of c mixing mixing them, for example vertical graph two Jure one coater (Fuji Industry Co., Ltd., Japan) about 3 with a stirrer in such Mix for 5 minutes.
上記混合,攪拌することにより、 顆粒状のものが得られる。 通常は、 このようにして得られた顆粒状のものを次の工程に付されるが、 さらに 該顆粒を 8メ ッ シュ( J I S規格)の篩を通過し、 1 0 0メ ッ シュ( J I S規格)の篩を通過しない大きさのものとするのが好ましい。 By mixing and stirring as described above, a granular product is obtained. Usually, the granules thus obtained are subjected to the next step. The granules are further passed through an 8 mesh (JIS standard) sieve, and are then passed through a 100 mesh (JIS standard) screen. It is preferably of a size that does not pass through a sieve of (Standard).
このようにして得られた顆粒は、 乾燥工程に付される。 該乾燥の方法 としては、 たとえば真空乾燥機中で約 4 0 °C ~ 6 0 °C ,約 0〜 5 mmH g , 約 8〜 1 6時間乾燥する、 通風乾燥機中で約 4 0〜 6 0 °C約 1〜3時 間乾燥する、 などが挙げられる。 The granules thus obtained are subjected to a drying step. The drying method includes, for example, drying in a vacuum dryer at about 40 ° C. to 60 ° C., about 0 to 5 mmHg, for about 8 to 16 hours, and about 40 to 6 hours in a ventilation dryer. Drying at 0 ° C for about 1 to 3 hours.
打錠用顆粒の製造の際に、 酸成分およびアル力リ成分を含有する発泡 顆粒に、 滑沢剤を倍散としたものを加えてもよい。 これは、 滑沢剤をそ のまま発泡顆粒と混合すると静電気により球形の大粒の顆粒になる傾向
があるので、 滑沢剤をたとえばアルカ リ成分あるいは酸成分と混合し篩 過することにより、 滑沢剤の顆粒化を防ぎ滑沢剤の効果をよくすること ができ、 そのため打錠を容易に行なうことができる。 又、 別途顆粒化さ れた炭酸のアル力リ金属塩を加えることによって、 得られた錠剤の発泡 力を増強することができる。 In the production of granules for tableting, a lubricant prepared by dispersing a lubricant may be added to the foamed granules containing an acid component and an alcohol component. This is because when the lubricant is mixed with foamed granules as they are, they tend to become spherical large granules due to static electricity. Therefore, by mixing a lubricant with, for example, an alkali component or an acid component and sieving, it is possible to prevent the lubricant from being granulated and to improve the effect of the lubricant, thereby facilitating tableting. Can do it. The foaming power of the obtained tablet can be enhanced by adding a separately granulated carbonic acid metal salt.
このようにして得られる乾燥された顆粒を錠剤にするには、 該顆粒を 打錠する。 打錠に際しては、 顆粒に、 所望により、 着色料,香料,甘味料, 調味料,結合剤,圧-縮潤滑剤などを添加したのち、 打錠工程に付してもよ い。 To make the dried granules thus obtained into tablets, the granules are compressed. At the time of tableting, a coloring agent, a flavor, a sweetener, a seasoning, a binder, a compression-contraction lubricant, and the like may be added to the granules, if desired, and then the tableting step may be performed.
上記着色料としては、 たとえばリボフラビン,タートラジン,サンセ、ソ トイエローなどが挙げられる。 上記香料としては、 たとえばオレンジォ ィル,レモンオイル,オレンジパウダー,レモンパウダーなどが挙げられ る。 上記甘味料としては、 たとえばサッカリ ン,アスパルテーム,砂糖な どが挙げられる。 上記調味料としては、 たとえばグルタ ミ ン酸ソーダ, 核酸調味料,コハク酸,粉 *カツォダシなどが挙げられる。 Examples of the coloring agent include riboflavin, tartrazine, sanse, soto yellow and the like. Examples of the flavor include orange oil, lemon oil, orange powder, lemon powder and the like. Examples of the sweetener include saccharin, aspartame, sugar and the like. Examples of the seasoning include sodium glutamate, nucleic acid seasoning, succinic acid, and powder * katsudashi.
上記活性成分が農薬である場合、 たとえば乳化剤などを添加し、 錠剤 としてもよい。 該乳化剤の例としては、 ラウリル硫酸ナ ト リ ウム,ポリ ビニルピロ リ ドン,ポリエチレングリ コール,多価アルコールの脂防酸ェ ステルたとえばスパン(ソルビタ ン脂肪酸エステル, At l as Powder Co .社 製,米国),ッィーン(ポリオキシエチレンソルビタ ンの脂肪酸エステル, At las Powder Co .社製),砂糖エステルなどが挙げられる。 When the active ingredient is an agricultural chemical, a tablet may be prepared by adding an emulsifier or the like, for example. Examples of the emulsifier include sodium lauryl sulfate, polyvinylpyrrolidone, polyethylene glycol, fatty acid ester of polyhydric alcohol such as span (sorbitan fatty acid ester, manufactured by Atlas Powder Co., USA) ), Sugars (fatty acid esters of polyoxyethylene sorbitan, manufactured by Atlas Powder Co.), sugar esters, and the like.
上記活性成分が動物用薬である場合、 たとえば乳化剤などを添加し、 錠剤としてもよい。 該乳化剤の例としては、 ラウリル硫酸ナトリウム, ポリ ビュルピロリ ドン,ポリエチレングリ コール,多価アルコールの脂肪 酸エステル,たとえばスパン,ツイーン,砂糖エステルなどが挙げられる。 打錠の際に用いられる結合剤としては、 たとえばポリ ビニルピロリ ド
ン,デキス ト リ ン,ァラビアゴム粉末,メチルセルロース,ヒ ドロキシプ σ ピルメチルセルロース,砂糖などが挙げられる。 When the active ingredient is a veterinary drug, for example, an emulsifier and the like may be added to make a tablet. Examples of the emulsifier include sodium lauryl sulfate, polyvinylpyrrolidone, polyethylene glycol, and fatty acid esters of polyhydric alcohols, such as spun, tween, and sugar esters. Examples of the binder used for tableting include polyvinyl pyrrolide. Dextrin, arabia gum powder, methylcellulose, hydroxy σ-pyrmethylcellulose, and sugar.
打錠の際に用いられる圧縮潤滑剤としては、 たとえばステアリ ン酸ナ ト リ ウム,安息香酸ナ ト リ ウム,ポリエチレングリ コール 4 0 0 0 ,ポリ エチレングリ コール 6 0 0 0などが挙げられる。 Examples of compression lubricants used for tableting include sodium stearate, sodium benzoate, polyethylene glycol 400, polyethylene glycol 600, and the like.
打錠は、 自体公知の通常用いられる方法により行なわれる。 Tableting is performed by a commonly used method known per se.
このようにして得られた発泡組成物において、 活性成分が医薬である 場合、 有効投与量となる量の医薬を含有する組成物をたとえば次のよう にして人に投与する。 When the active ingredient in the foamed composition thus obtained is a medicament, a composition containing an effective amount of the medicament is administered to a human, for example, as follows.
口の中に入れ発泡溶解あるいは懸蜀後、 飲み込むことにより経口投与す る。 Oral administration by swallowing after dissolving or suspending in the mouth.
水に入れ発泡させ溶液あるいは懸蜀液とし、 これを経口投与する。 Bubble in water to form a solution or suspension and orally administer it.
水に入れ発泡させ溶液あるいは懸蜀液としこれを皮膚に塗布し医薬を経 皮投与する。 A solution or suspension is prepared by foaming in water and applied to the skin to administer the drug transdermally.
浴槽の '愚に入れ発泡溶解あるいは懸蜀させ入浴し皮膚から医薬を吸収さPut the water in the bathtub and dissolve or suspend the bath to absorb the medicine from the skin.
"Gる。 "G
錠剤の場合は膣内に投与し発泡溶解あるいは懸濁させ医薬を吸収させる: 具体的には、 たとえば、 ァスコルビン酸を 1錠中約 5 0 0〜 1 0 0 0 mg含有する本発明の発泡錠 1〜 2錠を水約 6 0 - 2 0 0 mlに入れ発泡溶 解させ、 これを欽む。 In the case of tablets, the drug is absorbed by effervescent dissolution or suspension by intravaginal administration: Specifically, for example, the effervescent tablet of the present invention containing about 500 to 100 mg of ascorbic acid per tablet Put 1-2 tablets in about 60-200 ml of water to dissolve and foam.
本発明方法によって得られた発泡組成物において、 活性成分が食品で ある場合、 有効摂取量となる量の食品を含有する組成物をたとえば次の ようにして使用する。 In the foamed composition obtained by the method of the present invention, when the active ingredient is a food, a composition containing an amount of the food to be an effective intake is used, for example, as follows.
人の口の中に入れ発泡溶解あるいは懸蜀後飲み込む。 水に入れ発泡させ溶液あるいは懸蜀液としこれを人が飲む、。 Swallow after dissolving in foam or suspending in human mouth. Put it in water and make it into a solution or suspension, which people drink.
調理中にその材料に入れるあるいはふりかける。
一 9一 . . -- ' 一 組成物が顆粒である場合、 洗った野菜にこれをふりかける。 Add or sprinkle the ingredients during cooking. --- If the composition is a granule, sprinkle it on the washed vegetables.
具体的には、 たとえば、 生薬抽出物を含む茶を i錠中約 5 0 0〜 1 0 0 O mg含有する本発明の発泡錠 1 ~ 2錠を 4 0 ° 〜 8 0 °Cの湯約 6 0〜 1 0 O m Uこ入れ発泡溶解させ、 これを飲む。 Specifically, for example, 1 to 2 effervescent tablets of the present invention containing about 500 to 100 mg of tea containing a crude drug extract in i tablets at 40 ° C. to 80 ° C. 60 ~ 10 Om U squeeze foam to dissolve and drink this.
本発明方法によって得られた発泡組成物が農薬である場合、 有効撒布 量となる量の農薬を含む組成物は、 たとえば、 該組成物を水に入れ発泡 させ溶液あるいは懸蜀液としこれを対象生物に撒布する。 When the foamed composition obtained by the method of the present invention is a pesticide, a composition containing an effective amount of the pesticide to be sprayed is, for example, the composition is foamed in water to form a solution or a suspension. Spray on living things.
本発明方法によって得られた発泡組成物において、 活性成分が動物用 薬である場合、 有効投与量となる量の動物用薬を含有する組成物をたと えば次のようにして投与する。 When the active ingredient in the foamed composition obtained by the method of the present invention is an animal drug, a composition containing an effective amount of the animal drug is administered, for example, as follows.
水に入れ発泡させ、 溶液あるいは懸蜀液とし、 これを動物に飲ませる。 水に入れ発泡させ、 溶液あるいは懸蜀液とし、 これを動物にスプレーす る。 Bubble in water to form a solution or suspension, and give it to animals. Bubble in water to form a solution or suspension and spray it on animals.
水槽の水に入れ発泡させ、 溶解あるいは懸蜀させ、 その中で動物を水浴 させる。 In the water of the aquarium, foam, dissolve or suspend, and let the animals bath in the water.
本発明の目的物の発泡組成物が顆粒の場合、 該顆粒は、 微粉が少なく 粒の大きさが揃っているので、 ス トリ ツプ包装しやすく、 又ストリ ップ 包装のフィルム接着部に微粉がついて接着不良を起こすというようなこ とがない。 したがって、 該顆粒は、 その取扱いが容易である。 When the object foaming composition of the present invention is a granule, the granule has a small amount of fine powder and a uniform particle size, so that it is easy to be strip-packaged, and the fine powder is applied to the film bonding portion of the strip package. There is no such thing as causing poor adhesion due to sticking. Therefore, the granules are easy to handle.
さらに、 該顆粒は、 大きく揃った顆粒であり、 水に投入した場合、 底 に沈んだ後良好に発泡する。 Furthermore, the granules are large uniform granules, and when poured into water, foam well after sinking to the bottom.
本発明方法において、 発泡組成物が顆粒であるものを製造する場合、 使用する水が少量なので乾燥が容易である。 また、 湿めらされた酸成分 とアルカリ成分とを混合すると、 大きく固まらず、 均一な顆粒ができる ので、 通常の顆粒製造工程に必要とされる乾燥工程前の製粒工程を省略 することができる。 さらに、 該顆粒は、 乾燥後、 粒同志はあまりひっつ
いていないので篩過するだけで簡単に整粒できる。 したがって、 該顆粒 の工業的生産は容易である。 In the method of the present invention, when the foamed composition is in the form of granules, drying is easy because a small amount of water is used. Also, if the moistened acid component and alkali component are mixed, uniform granules can be formed without being hardened largely, so that the granulation step before the drying step, which is required for the usual granule manufacturing process, can be omitted. it can. Furthermore, after the granules are dried, It is not sized and can be easily sized by sieving. Therefore, industrial production of the granules is easy.
本発明方法において、 発泡組成物が錠剤であるものを製造する場合、 従来の発泡錠の製造では酸成分とアル力リ成分を別々に練合,造粒,乾燥: 製粒しなければならないが、 本発明方法では酸成分とアルカリ成分とを 混合してから練合,造粒,乾燥,製粒することができるので、 製造工程数 が少なぐてすむ。 In the method of the present invention, when the effervescent composition is a tablet, the acid component and the alcohol component must be separately kneaded, granulated, and dried in the conventional production of effervescent tablets. According to the method of the present invention, kneading, granulation, drying and granulation can be carried out after mixing the acid component and the alkali component, so that the number of production steps can be reduced.
本発明方法で得られた顆粒は、 微粉が少ないので、 錠剤の製造時には 滑沢剤の使用量が少なくて済み、 打錠性が良い。 また、 該顆粒は微粉が 少ないので、 打錠の際のひっつき,ぎしつきを防ぐことができる。 Since the granules obtained by the method of the present invention have a small amount of fine powder, a small amount of lubricant is required at the time of tablet production, and the tableting property is good. Further, since the granules have a small amount of fine powder, it is possible to prevent sticking and sticking during tableting.
本発明の発泡組成物において、 該組成物が錠剤である場^、 該綻剤は、 水中における崩壌時間が早く、 水中にあっては長く水底に沈んでいると いう発泡錠に要求される性質を具備している。 . In the effervescent composition of the present invention, when the composition is a tablet, the disintegrant is required for an effervescent tablet that has a long disintegration time in water and is long submerged in water. Has properties. .
本発明方法によると、 錠剤の硬度を約 2〜 1 5 kgぐらい迄調節するこ とができる。 崩壞時間は硬度が大きくなると遅くなるので用途に応じて 崩壞時間の調節も可能となる。 According to the method of the present invention, the hardness of the tablet can be adjusted to about 2 to 15 kg. The decay time becomes slower as the hardness increases, so the decay time can be adjusted according to the application.
本発明方法によると、 錠剤の発泡状態も調節可能で、 硬度を 2〜4 kg にすると細かい大量の泡が発生し 1分以内に崩壞する。 硬度を 5 kg以上 にすると泡が大きくなり、 崩壌時間も 1分以上になる。 瓶中に、 本発明 方法で得られた 1 0錠のビタ ミ ン C含有発泡錠をシリ力ゲルと共にネジ キャップをして 6 0 °C , 1力月保存しても色,味,発泡状態,発泡時間,含 量に大きな変化はないので、 本発明方法で得られたビタ ミ ン C含有発泡 錠は、 室温では少なく とも 2〜3年は安定と思われる。 特にビタミ ン 0· は変色しやすい性質を持っており、 熟,水分に対して不安定であるが、 該錠剤中では安定である。 According to the method of the present invention, the foaming state of the tablet can be adjusted. When the hardness is set to 2 to 4 kg, a large amount of fine bubbles are generated and collapse within 1 minute. When the hardness is set to 5 kg or more, the foam increases and the crushing time becomes 1 minute or more. In a bottle, 10 tablets of vitamin C-containing effervescent tablets obtained by the method of the present invention were screw-capped together with a silylation gel and stored at 60 ° C for 1 month. Since there is no significant change in the foaming time and content, the foamed tablet containing vitamin C obtained by the method of the present invention is considered to be stable at room temperature for at least 2 to 3 years. In particular, vitamin 0 has the property of easily discoloring and is unstable to ripening and moisture, but is stable in the tablet.
発明を実施するための最良の形態
次に実施例をもって本発明をさらに具体的に説明する。 なお、 パ一セ ン トは、 とく にことわりのないかぎり、 w/w%を示す。 BEST MODE FOR CARRYING OUT THE INVENTION Next, the present invention will be described more specifically with reference to examples. The percentages are w / w% unless otherwise specified.
実施例 1 Example 1
次の処方 Aの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formulation A composition was prepared.
処方 A Prescription A
注 1 C - 9 7 515.5mg (ビタ ミ ン Cとして 500mg) 注 2 無水クェン酸 .. 300 mg Note 1 C-97 7 515.5 mg (500 mg as vitamin C) Note 2 Cyanic anhydride ..300 mg
注 3 重炭酸ナ ト リ ウム 550 mg Note 3 Sodium bicarbonate 550 mg
サッカ リ ンナ ト リ ウム 10 mg Saccharin sodium 10 mg
安息香酸ナト リ ウム 50 mg Sodium benzoate 50 mg
叶 1,425.5mg( 1錠中) Kano 1,425.5mg (per tablet)
注 1 : C - 9 7: 日本特公昭 5 8 - 4 0 3号公報の実施例 1に記載 の方法で製造した L—ァスコルビン酸 9 7 % (w/w)およ CKコ —ンスターチ 3 % (w/w)を含む顆粒。 以下の実施例 2〜4も 同様。 Note 1: C-97: 97% (w / w) of L-ascorbic acid and 3% of CK starch manufactured by the method described in Example 1 of Japanese Patent Publication No. 58-403. (w / w). The same applies to the following Examples 2 to 4.
注 2 無水クェン酸は、 4 0メ ッ シュ( J I S規格)の篩を通過する 顆粒を用いた。 以下の実施例 2〜8 も同様。 Note 2 Granules passing through a 40 mesh (JIS standard) sieve were used for cunic anhydride. The same applies to the following Examples 2 to 8.
注 3 重炭酸ナトリゥムは、 4 0メ ッ シュ(J I S規格)の篩を通過 する顆粒を用いた。 以下の実施例 2〜8 も同様。 Note 3 For sodium bicarbonate, granules that passed through a 40 mesh (JIS standard) sieve were used. The same applies to the following Examples 2 to 8.
製造法 Manufacturing method
(1) 黄色 5号(sunset yel low) 5 gを水に溶かし、 1 0 Omlの着色水と した。 重炭酸ナトリウム 1 . 8 kgをバーチカル ' グラニユレ一ターに入 れ、 高速(6 0 O rpm)で羽根を 5分間回転させた後、 上記着色水 1 8 ml を少量ずつ加えながら、 5分間回転させた。 別途、 C— 9 7 2. 0 6 2kgと無水クェン酸粉末 1. 2 kgとをバーチカル · ダラ二ユレ一ターに 入れ、 高速(6 0 0 rpm)で羽根を 5分間回転させた後、 上記着色水 3 3
mlを少量ずつ加えながら 5分間回転させた。 これに、 上記で得た着色し 加湿された重炭酸ナトリウムを加え、 3分間混合した。 (1) 5 g of yellow No. 5 (sunset yellow) was dissolved in water to obtain 10 Oml of colored water. 1.8 kg of sodium bicarbonate was placed in a Vertical Granulator, and the blades were rotated at high speed (60 rpm) for 5 minutes. Then, while adding 18 ml of the above colored water little by little, the mixture was rotated for 5 minutes. Was. Separately, put 2 kg of C-97.26.02 and 1.2 kg of citrate anhydride powder into a vertical drabener, rotate the blade at high speed (600 rpm) for 5 minutes, and then Colored water 3 3 Spin for 5 minutes while adding small portions of ml. To this was added the colored and humidified sodium bicarbonate obtained above and mixed for 3 minutes.
得られた混合物を、 真空乾燥機中で、 40て.5舰113で 1 6時間乾燥 し、 発泡顆粒を製造した。 The obtained mixture was dried in a vacuum drier at 40 to 0.5 舰 113 for 16 hours to produce expanded granules.
(2) 重炭酸ナトリウム 1 kgをバーチカル♦ ダラ二ユレ一ターに入れ、 高 速(60 Orpm)で羽根を 5分間回転させた後、 上記(1)で得られたのと同 様の着色水 1 Omlを少量ずつ加えながら、 5分間回転させた。 (2) Place 1 kg of sodium bicarbonate in a vertical ダ 二 二 二 一 タ ー タ ー タ ー 、 、 さ せ 後 た 後 後 後 後 5 5 5 後 5 5 5 着色 着色 後 後 後Spin for 5 minutes while adding 1 Oml little by little.
得られた着色し加湿された重炭酸ナトリゥムを真空乾燥機中で 40°C, 5mmHgで 1 6時間乾燥し、 着色重炭酸ナトリゥムを製造した。 The resulting colored and moistened sodium bicarbonate was dried in a vacuum drier at 40 ° C. and 5 mmHg for 16 hours to produce colored sodium bicarbonate.
(3) 上記(2)で得られた着色重炭酸ナトリウム 40 Og,サッカリンナト リゥム粉末 4 Og,安息香酸ナトリゥム粉末 20 Ogを混合し、 32メ ッ シュ(J I S規格)の篩で 3回篩過した。 この内の 586 gと、 上記(1)で 得られた発泡顆粒 5 , 00 Ogとを関係湿度 5 0%の部屋でバーチカル · グラニユレ一ターに入れ高速(60 Orpm)で羽根を 3分藺回転させ混合 した。 (3) 40 Og of colored sodium bicarbonate obtained in (2) above, 4 Og of saccharin sodium powder and 20 Og of sodium benzoate powder are mixed, and sieved three times with a 32 mesh (JIS standard) sieve. did. 586 g of this and 5,000 g of the foamed granules obtained in (1) above were placed in a vertical granulator in a room with a relative humidity of 50%, and the blades were rotated at high speed (60 Orpm) for 3 minutes. And mixed.
(4) 打錠機としてストークス B 2 (F.J. STOKES CORPOEATIOJi製,米国)を 用い、 打錠機の打錠テーブル周辺に低湿度の圧力空気(22°C,関係湿度 1 0%)を吹き込み、 忤臼の付近の関係湿度を 1 0%とした。 打錠機の 回転数を 1 4回転/分とし、 1 5匪直径の隅丸杵を用い、 上記(3)で得 られた混合物を打錠した。 (4) Using Stokes B2 (made by FJ STOKES CORPOEATIOJi, USA) as a tableting machine, blow low pressure air (22 ° C, relative humidity 10%) around the tableting table of the tableting machine. The relative humidity around the mortar was 10%. The mixture obtained in the above (3) was tableted using a tableting machine with a rotation speed of 14 revolutions / minute and a corner punch with a diameter of 15 band.
このようにして得られた発泡錠剤の直径,厚み,重量および硬度,錠剤 を 24°Cの水 1 00mlに常圧下に溶解した場合の発泡時間,発 ^状態, PHおよび味を以下に示す。
実施例 2 The diameter, thickness, weight and hardness of the effervescent tablet obtained in this way, the effervescence time, efflux state, PH and taste when the tablet is dissolved in 100 ml of water at 24 ° C under normal pressure are shown below. Example 2
次の処方 Bの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formulation B formulation was produced.
処方 B Prescription B
C - 97 515.5mg (ビタミ ン Cとして 500mg) 無水クェン酸 450 ig C-97 515.5mg (500mg as vitamin C) Cyanic anhydride 450 ig
重炭酸ナ ト リ ウム 525 mg 525 mg sodium bicarbonate
サッカリ ンナ ト リ ウム 7.5mg Saccharinium sodium 7.5mg
香料サンダーコ一 ト ン 22.5mg Perfume Sanderton 22.5mg
安息香酸ナ ト リ ウム 50 mg. - 計 · 1,57.0.5mg( 1錠中) Sodium benzoate 50 mg.-Total · 1,57.0.5 mg (per tablet)
(1) 黄色 5号(sunset yellow) 5 gを水に溶かし、 1 00mlの着色水と した。 重炭酸ナトリウム 1. 5 kgをバーチカル · ダラ二ユレ一ターに入 れ、 高速(60 Orpm)で羽根を 5分間回転させた後、 上記着色水 1 5 ml を少量ずつ加えながら、 5分間回転させた。 別途、 G— 97 2. 06 2 kgと無水クェン酸 1. 8 kgとをバーチカル * グラニユレ一ターに入れ, 高速(60 Orpm)で羽根を 5分間回転させた後、 上記着色水 3 8 ndを少 量ずつ加えながら 5分間回転させた。 これに、 上記で得た着色し加湿さ れた重炭酸ナ ト リ ウムを加え、 3分間混合した。 (1) 5 g of sunset yellow 5 was dissolved in water to make 100 ml of colored water. 1.5 kg of sodium bicarbonate was placed in a vertical drier, and the blades were rotated at high speed (60 Orpm) for 5 minutes. Then, while adding 15 ml of the above colored water little by little, the mixture was rotated for 5 minutes. Was. Separately, put 2 kg of G-97 2.06 and 1.8 kg of citrate anhydride into a vertical * granulator and rotate the blade at high speed (60 Orpm) for 5 minutes. Rotate for 5 minutes while adding little by little. To this, the colored and moistened sodium bicarbonate obtained above was added and mixed for 3 minutes.
得られた混合物を、 真空乾燥機中で、 40°C, 5匪 Hgで 1 6時間乾燥 し、 発泡顆粒を製造した。 The obtained mixture was dried in a vacuum dryer at 40 ° C. and 5 Hg for 16 hours to produce expanded granules.
(2) 重炭酸ナトリウム 1 kgをバーチカル · グラニユレ一ターに入れ、 高
速(6 0 O rpm)で羽根を 5分間回転させた後、 上記(1)で得られたのと同 様の着色水 1 0 mlを少量ずつ加えながら、 5分間回転させた。 (2) Add 1 kg of sodium bicarbonate to the vertical granulator, After rotating the blade at a high speed (60 O rpm) for 5 minutes, the blade was rotated for 5 minutes while adding 10 ml of the same colored water as obtained in the above (1) little by little.
得られた着色し加湿された重炭酸ナトリゥムを真空乾燥機中で 4 0°C, 5 mmHgで 1 6時間乾燥し、 着色重炭酸ナトリゥムを製造した。 The obtained colored and moistened sodium bicarbonate was dried in a vacuum drier at 40 ° C. and 5 mmHg for 16 hours to produce colored sodium bicarbonate.
(3) 上記(2)で得られた着色重炭酸ナトリウム 6 0 Og,サッカリ ンナト リゥム粉末 3 Og,安息香酸ナトリゥム粉末 2 0 Og,香料サイダーコート ン粉末 9 Ogを混合し、 3 2メ ッシュ(J I S規格)の篩で 3回篩過した。 この内の 9 2 Ogと、 上記(1)で得られた発泡顆粒 5 0 0 Ogとも関係 S 度 5 0 %の部屋でパーチカル · グラニユレ一ターに入れ高速(6 0 0 rpm) で羽根を 3分間回転させ混合した。 (3) 60 Og of the colored sodium bicarbonate obtained in (2) above, 3 Og of saccharin sodium powder, 20 Og of sodium benzoate powder and 9 Og of perfume cider coat powder were mixed, and the mixture was mixed with 32 mesh ( (JIS standard) sieve three times. Among them, 92 Og and the foamed granules obtained in the above (1) are also related to 500 Og. In a room of 50% in S degree, put in a vertical granulator and rotate the blades at high speed (600 rpm). Mix by spinning for minutes.
(4) 打錠機としてストークス B 2を用い、 打錠機の打錠テーブル周辺に 低温度の圧力空気(2 2 ,関係湿度 1 0 %)を吹き込み、 杵臼の付近の 関係湿度を 1 Q %とした。. . (4) Stokes B2 was used as a tableting machine, and low-temperature pressurized air (22, relative humidity 10%) was blown around the tableting table of the tableting machine, and the relative humidity near the punch and die was reduced to 1 Q%. And .
打錠機の回転数を 1 4回転/分とし、 1 5mm直径の隅丸杵を用い、 上 記(3)で得られた混合物を打錠した。 The rotation speed of the tableting machine was set at 14 revolutions / minute, and the mixture obtained in the above (3) was tableted using a 15 mm-diameter corner round punch.
このようにして得られた発泡錠剤の直径,厚み,重量および硬度,錠剤 を 24°Cの水 1 0 Omlに常圧下に溶解した場合の発泡時間,発泡状態, pH,味,直径,厚みおよび重量を以下に示す。 The diameter, thickness, weight and hardness of the effervescent tablet thus obtained, the effervescence time when the tablet is dissolved in 10 Oml of water at 24 ° C under normal pressure, effervescent state, pH, taste, diameter, thickness and The weight is shown below.
次の処方 Cの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formulation C composition was produced.
処方 C
C - 9 7 5i5.5mg (ビタ ミ ン Cとして 500mg) 無水クェン酸 450 mg Prescription C C-97 5i5.5mg (500mg as vitamin C) Cyanic anhydride 450mg
重炭酸ナ ト リ ウム 500 mg 500 mg sodium bicarbonate
サッカ リ ンナ ト リ ウム 5 mg Saccharin sodium 5 mg
香料サイダーコ一 トン 22.5mg Perfume cider coton 22.5mg
安息香酸ナ ト リ ウム 50 mg Sodium benzoate 50 mg
計 1,543 mg(l錠中) Total 1,543 mg (in 1 tablet)
製造法 Manufacturing method
(1) 黄色 5号(sunset yel low) 5 gを水に溶かし、 1 0 Omlの着色水と した。 (1) 5 g of yellow No. 5 (sunset yellow) was dissolved in water to obtain 10 Oml of colored water.
重炭酸ナトリウム 1 . 8 kgをバーチカル♦ ダラ二ユレ一ターに入れ、 高速(6 0 O rpm)で羽根を 5分間回転させた後、 上記着色水 1 8 mlを少 量ずつ加えながら、 5分間回転させた。 · ' 1.8 kg of sodium bicarbonate is placed in a vertical ♦ double-drainer, and the blades are rotated at high speed (60 O rpm) for 5 minutes. Rotated. · '
別途、 C— 9 7 2. 0 6 2 kgと無水クェン酸粉未 1 . 8 kgとをバー チカル · グラニユレ一ターに入れ、 高速(6 0 O rpm)で羽根を 5分間回 転させた後、 上記着色水 3 2mlを少量ずつ加えながら 5分間回転させた。 これに、 上記で得た着色し加湿された重炭酸ナトリウムを加え、 3分間 混合した。 Separately, put C-972.062 kg and 1.8 kg of citrate anhydride powder into a vertical granulator, and rotate the blade at high speed (60 O rpm) for 5 minutes. The solution was rotated for 5 minutes while adding 32 ml of the above colored water little by little. To this, the colored and moistened sodium bicarbonate obtained above was added and mixed for 3 minutes.
得られた混合物を、 真空乾燥機中で、 4 0て, 5匪118で 1 6時間乾燥 し、 発泡顆粒を製造した。 The obtained mixture was dried in a vacuum drier at 40, 5 with 118 for 16 hours to produce expanded granules.
(2) 重炭酸ナトリウム 1 kgをバーチカル · ダラ二ユレ一ターに入れ、 高 速(6 0 O rpm)で羽根を 5分間回転させた後、 上記(1)で得られたのと同 様の着色水 1 Omlを少量ずつ加えながら、 5分間回転させた。 (2) Place 1 kg of sodium bicarbonate in a vertical drier, rotate the blades at a high speed (60 O rpm) for 5 minutes, and use the same method as obtained in (1) above. The mixture was rotated for 5 minutes while adding 1 Oml of coloring water little by little.
得られた着色し加湿された重炭酸ナトリゥムを真空乾燥機中で 4 0 °C 5隱 Hgで 1 6時間乾燥し、 着色重炭酸ナトリゥムを製造した。 The obtained colored and humidified sodium bicarbonate was dried in a vacuum dryer at 40 ° C. and 5 Hg for 16 hours to produce colored sodium bicarbonate.
(3) 上記(2)で得られた着色重炭酸-ナトリウム 2 0 0 g,サッカリ ンナト
リゥム粉末 2 Og,安息香酸ナトリゥム粉末 2 0 Og,香料サイダーコート ン粉末 9 Ogを混合し、 3 2メ ッシュ(J I S規格)の篩で 3回篩過した。 この内の 4 5 1 gと、 上記(1)で得られた発泡顆粒 5 0 0 Ogとを関係湿 度 5 0 %の部屋でパーチカル . グラニュレーターに入れ高速(6 0 0 rptn) で羽根を 3分間回転させ混合した。 (3) 200 g of the colored sodium bicarbonate obtained in (2) above, saccharinato A mixture of 2 Og of powdered lithium powder, 20 Og of sodium benzoate powder, and 9 Og of perfume cider coat powder was sieved through a 32 mesh (JIS standard) sieve three times. Of these, 45 1 g and the foamed granules obtained in (1) above, 500 Og, were placed in a vertical granulator in a room with a relative humidity of 50%, and the blades were spun at high speed (600 rptn). Spin for 3 minutes to mix.
(4) 打綻機としてス ト一クス B 2を用い、 打錠機の打錠テーブル周辺に 低湿度の圧力空気(2 2て,関係湿度 1 0 %)を吹き込み、 杵臼の付近の 関係湿度を 1 0 %とした。 打錠機の回転数を 1 4回転/分とし、 1 5 mm 直径の隅丸杵を用い、 上記(3)で得られた混合物を打錠した。 (4) Using Stroke B2 as the crushing machine, blow low-pressure air (22%, relative humidity: 10%) around the tableting table of the tableting machine, and reduce the relative humidity near the punch and die. Was set to 10%. The mixture obtained in the above (3) was tableted using a 15 mm diameter corner round punch with a tableting machine rotating at 14 revolutions / minute.
このようにして得られた発泡錠剤の直径,厚み,重量および硬度,錠剤 を 2 4 °Cの水 1 0 0mlに常圧下に溶解した場合の発泡時間,発泡伏態, pH,味を以下に示す。 The diameter, thickness, weight, and hardness of the effervescent tablet thus obtained, and the foaming time, foaming state, pH, and taste when the tablet is dissolved in 100 ml of water at 24 ° C under normal pressure are as follows. Show.
次の処方 Dの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formulation D composition was produced.
処方 D Prescription D
C - 9 7 247 mg (ビタ ン として 240mg) ァスピリ ン微細粉 400 mg C-9 7 247 mg (240 mg as vitamin) Aspirin fine powder 400 mg
無水クェン酸 1,200 mg Cyanic anhydride 1,200 mg
重炭酸ナ ト リ ウム 1,800 mg Sodium bicarbonate 1,800 mg
ポリエチレンダリ コール 6000 20 mg Polyethylene Dalicol 6000 20 mg
サッカ リ ンナ ト リ ウム 10 mg Saccharin sodium 10 mg
安息香酸ナ ト リ ウム 100 mg
計 3,777 mg(l錠中) Sodium benzoate 100 mg Total 3,777 mg (in 1 tablet)
(1) 重炭酸ナトリウム 1. 8kgをバーチカル♦ ダラ二ユレ一ターに入れ 高速(60 Orpm)で羽根を 5分間回転させた後、 水 2 Omlを少量ずつ加 えながら 5分間回転させた。 (1) Sodium bicarbonate (1.8 kg) was placed in a vertical Daraniurator, and the blades were rotated at a high speed (60 Orpm) for 5 minutes, and then rotated for 5 minutes while adding 2 Oml of water little by little.
(2) 別途、 C— 97 247 g,アスピリ ン微細粉末 400 g,無水クェン 酸 1 , 2 0 0 g,ポリエチレンダリコール粉末 20 gをバーチカル · グラニュ レーダーに入れ高速(6 0 Orpm)で羽根を 5分間回転させた後、 水 20 mlを少量ずつ加えながら 5分間回転させた。 加湿した重炭酸ナト リウム を加え 3分間混合した。 (2) Separately, put C-97 247 g, aspirin fine powder 400 g, citrate anhydride 1,200 g, and polyethylene dalicol powder 20 g into a vertical granule radar and set the blades at high speed (60 Orpm). After rotating for 5 minutes, the mixture was rotated for 5 minutes while adding 20 ml of water little by little. The humidified sodium bicarbonate was added and mixed for 3 minutes.
(3) 上記(2)で得られた混合物を真空乾燥機中で 1 6時間(40 °C , 5 mm Hg)乾燥した。 (3) The mixture obtained in the above (2) was dried in a vacuum drier for 16 hours (40 ° C., 5 mm Hg).
(4) 乾燥後の混合物を 32メ ッ シュ篩過しそのうち 3. 5 kgをとりサッ カ リ ンナトリゥム粉末 9. 3 g及び安息香酸ナトリゥム粉末 93gを加え てバーチカル · グラニユレ一ターに入れ高速(60 Orpm)で羽根を 3分 間回転させ混合した。 混合物を直径 2 5隠の平面杵を甩いて直径約 2 δ mm厚み約 6讓 1錠当りの重量 3 800 mgの錠剤をつく つた。 1 6ての水 1 0 0 mlに常圧下で溶解した場合の発泡時間は 1分 1 5秒であった。 実施例 5 (4) The dried mixture is sieved through a 32 mesh sieve, 3.5 kg of the mixture is added, 9.3 g of saccharine sodium powder and 93 g of sodium benzoate powder are added, and the mixture is placed in a vertical granulator, and high-speed (60 (Orpm) for 3 minutes to mix. The mixture was used to make a tablet having a diameter of about 2 δ mm and a thickness of about 6 rows, and a weight of 3 800 mg per tablet using a flat punch with a diameter of 25. When dissolved in 100 ml of water under normal pressure, the foaming time was 1 minute and 15 seconds. Example 5
次の処方 Eの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formulation E composition was prepared.
処方 E Prescription E
注 1 粉末酒 · アルコック 1,000 mg Note 1 Powdered sake · Alcock 1,000 mg
無水クェン酸 し000 mg Citric anhydride 000 mg
重炭酸ナ ト リ ウム 1,000 mg Sodium bicarbonate 1,000 mg
安息香酸ナト リ ウム 100 mg Sodium sodium benzoate 100 mg
計 3,100 mg(l錠中)
注 1 : 粉末酒 · アルコック 日本特公昭 4 7 - 3 9 3 5 5号公報参照 ,ウォッカタイプ,アルコール分 3 0. 5 w/w¾ Total 3,100 mg (in 1 tablet) Note 1: Powdered sake · Alcock See Japanese Patent Publication No. 47-39355, vodka type, alcohol content 30.5 w / w w
製造法 Manufacturing method
(1) クェン酸 1 0 Ogと粉末酒アルコ、ソク 1 0 0 gを混合し 3 mlの水をス プレーした。 (1) 100 g of cunic acid, 100 g of Alcohol powder and 100 g of Sok were mixed and sprayed with 3 ml of water.
(2) 別途重炭酸ナトリウム 1 0 Ogに 1 mlの水をスプレーした。 (2) Separately, 1 ml of water was sprayed on 10 Og of sodium bicarbonate.
(3) (1)及び(2)で得られたものを混合後通風乾燥機中で 5 0°C 2時間 乾燥した。 (3) After mixing the products obtained in (1) and (2), the mixture was dried in a ventilation dryer at 50 ° C for 2 hours.
(4) 乾燥後の混合物 2 5 Ogと安息香酸ナトリウム粉末 8. 1 gとを混合 し、 直径 2 Ommの平面杵を用いて直径約 2 0 mm厚み約 7 mm 1錠当りの重 量 3. l g,硬度 5kgの錠剤をつく った。 2 0ての水 (4) Mix 25 Og of the dried mixture and 8.1 g of sodium benzoate powder, and use a flat punch with a diameter of 2 Omm to obtain a weight of about 20 mm in diameter and about 7 mm in thickness per tablet 3. I made tablets with a hardness of 5 kg. 20 water
1 0 0 mlに常圧下で溶解した場合の発泡時間は 3 7秒であった。 The foaming time when dissolved in 100 ml under normal pressure was 37 seconds.
実施例 6 · Example 6
次の処方 Fの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formula F composition was produced.
処方 F Formulation F
アスパルテーム(甘味料) 100 mg Aspartame (sweetener) 100 mg
β -ラウ トース 600 mg β-lautose 600 mg
無水クェン酸 . 200 ig Cuic anhydride .200 ig
重炭酸ナトリウム 1,000 mg Sodium bicarbonate 1,000 mg
安息香酸ナトリウム 45 mg Sodium benzoate 45 mg
計 2,945 mg(l錠当り) 製造法 Total 2,945 mg (per 1 tablet)
(1) アスパルテーム粉末 1 0g,,S—ラク トース粉末 6 Og及び無水クェ ン酸 1 2 0 gを混合し 2 mlの水をスプレーした。 (1) 10 g of aspartame powder, 6 Og of S-lactose powder and 120 g of citric anhydride were mixed and sprayed with 2 ml of water.
(2) 別途重炭酸ナトリウム 1 0 Ogに 1 idの水をスプレーした。 (2) Separately, 10 id of sodium bicarbonate was sprayed with 1 id of water.
(3) (1)及び(2)で得られたものを混合後通風乾燥機中で 5 0°C, 2時間
阜乙 Tこ。 (3) After mixing the products obtained in (1) and (2), in a draft dryer at 50 ° C for 2 hours Fuoto Toko.
(4) 乾燥後の混合物 2 5 Ogと安息香酸ナ ト リウム粉末 3. 9 gとを混合 し直径 2 0 mmの平面杵を用いて直径 2 0. 1 5 mm,厚み 7. 1 し重量 3 Og,硬度 4. 7 kgの錠剤をつく った。 2 5°Cの水 1 0 Omlに常圧下で溶 解した場合の発泡時間は 2分 1 5秒であった。 (4) Mix 25 Og of the dried mixture with 3.9 g of sodium benzoate powder, and use a 20 mm diameter flat punch to produce a diameter of 20.1 mm, a thickness of 7.1 and a weight of 3 Og, hardness 4.7 kg tablets were made. The foaming time when dissolved in 10 Oml of water at 25 ° C under normal pressure was 2 minutes and 15 seconds.
実施例 7 Example 7
次の処方 Gの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formula G composition was produced.
処方 G Prescription G
注 i スポーツ ドリ ンクタケダ 1,300 mg Note i Sports drunk keda 1,300 mg
無水クェン酸 1,300 mg Cyanic anhydride 1,300 mg
重炭酸ナト リ ウム 500 mg Sodium bicarbonate 500 mg
安息香酸ナ ト リ ウム 45 mg Sodium benzoate 45 mg
, 計 3,145 mg(l錠当り) 注 1 スポーツ ドリ ンクタケダ: ビタ ミ ン ♦ ミ ネラル混合ソフ ト ド . リ ンク。 スポーツ ドリ ンク 1 3 g中下記ビタ ミ ン ♦ ミ ネラルを 含有する。 , Total 3,145 mg (per tablet) * 1 Sports drinks: Vitamin ♦ Mineral mixed soft drink. The following vitamins in 13 g of sports drinks ♦ Contains minerals.
ビタ ミ ン C SOOmg, ナイァシン 13mg, リ ン酸 49mg, ビタ ミ ン ^ O.Smg, ナ ト リ ウム 80mg, マグネシウム 4mg, ビタ ミ ン B2 i.lmg, カ リ ウム 78mg, クロール 106mg。 製造法 Vita Mi down C SOOmg, Naiashin 13mg, Li phosphate 49mg, Vita Mi down ^ O.Smg, Na door Li Umm 80mg, magnesium 4mg, Vita Mi emissions B 2 i.lmg, mosquito Li Umm 78mg, crawl 106mg. Manufacturing method
(1) スポーツ ドリ ンクタケダ粉末 1 3 Og,無水クェン酸 1 3 Ogを混合 し 3 mlの水をスプレーした。 (1) 13 Og of sports drink powder and 13 Og of citrate anhydride were mixed and sprayed with 3 ml of water.
(2) 別途重炭酸ナトリウム 5 Ogに水 1 mlをスプレーした。 (2) Separately, 1 ml of water was sprayed on 5 Og of sodium bicarbonate.
(3) )及び(2)で得られたものを混合後通風乾燥機中で 5 0°C, 2時間 乾燥した。 After mixing (3)) and (2), the mixture was dried in a ventilation dryer at 50 ° C for 2 hours.
(4) 乾燥後の混合物 3 0 Ogと安息香酸ナトリウム粉末 4. 3 gを混合し
直径 2 0隨の平面杵を用いて直径 2 0. 1 2 mm,厚み 7. 4 l mm,重量 3. 1 5g,硬度 6. 5 kgの錠剤をつく った。 2 5 °Cの水 1 0 0 mlに常圧下で 溶解した場合の発泡時間は 1分 1 0秒であった。 (4) 30 g of the dried mixture and 4.3 g of sodium benzoate powder were mixed. Tablets having a diameter of 20.1 mm, a thickness of 7.4 lmm, a weight of 3.15 g, and a hardness of 6.5 kg were prepared using a flat punch having a diameter of 20 mm. The foaming time when dissolved in 100 ml of water at 25 ° C under normal pressure was 1 minute and 10 seconds.
実施例 8 Example 8
次の処方 Hの組成を有する発泡錠剤を製造した。 An effervescent tablet having the following formula H composition was produced.
処方 H Prescription H
注 1 Alete Kindertee(Nestle' Alete GmbH) 1,400 mg Note 1 Alete Kindertee (Nestle 'Alete GmbH) 1,400 mg
(ァレテキンダーテー ネッスルァレテゲーェムベーハー社製,スイス) 無水クェン酸 700 mg (Altekindate Nessle Altegembaeher, Switzerland) Cyanic anhydride 700 mg
重炭酸ナトリウム 700 mg 700 mg sodium bicarbonate
安息香酸ナトリウム 45 mg Sodium benzoate 45 mg
計 2,845 mga錠当り) 2,845 mga tablets in total)
' 注 1 : ァレテキンダーテ一 - . 'Note 1: Alekindate-.
スイス,ネッスルァレテゲーェムベーハー社製の茴香,ジャス ミ ン,甘草,力ミ レ,ァニス,たちじゃこうそう,メ リ ッサノヽッ力, 香水ハッ力の植物抽出物を含む顆粒化された茶 Granulated with plant extracts from Fenx, Jasmine, Licorice, Power Millet, Anise, Tachijaso, Melissanod Power and Perfume Ha Power from Nesslare Tegembecher, Switzerland. Tea
製造法 Manufacturing method
(1) ァレテキンダーテ一(顆粒) 1 4 Ogと無水クェン酸 7 Ogを混合し 2 mlの水をスプレーした。 (1) 14 Og of altekindate (granules) and 7 Og of citrate anhydride were mixed and sprayed with 2 ml of water.
(2) 別途重炭酸ナトリウム 7 0 gに 1 mlの水をスプレーした。 . (2) Separately, 70 ml of sodium bicarbonate was sprayed with 1 ml of water. .
(3) (1)及び(2)で得られたものを混合後通風乾燥機中で 5 0°C, 2時間 乾燥した。 (3) After mixing the products obtained in (1) and (2), they were dried in a ventilation dryer at 50 ° C for 2 hours.
(4) 乾燥後の混合物 2 5 Ogと安息香酸ナトリゥム粉末 4. Ogを混合し 直径 2 0 mmの平面杵を用いて直径 2 0. 1 9匪,厚み 6. 5 3 mm,重量 2. 8 5g,硬度 1 1 kgの錠剤をつく つた。 5 0°Cの水 6 Omlに常圧下で溶解 した場合の発泡時間は 5 0秒であった。
産業上の利用可能性 (4) 25 Og of the dried mixture and sodium benzoate powder 4. Mix Og and use a 20 mm diameter flat punch to obtain a diameter of 0.19, a thickness of 6.53 mm, and a weight of 2.8. Tablets of 5 g and hardness of 1 kg were made. The foaming time when dissolved in 6 Oml of water at 50 ° C under normal pressure was 50 seconds. Industrial applicability
本発明の組成物は、 崩壞時間が早く、 速やかに発泡する医薬組成物 食品組成物,農薬組成物,動物用薬組成物として利用できる。
INDUSTRIAL APPLICABILITY The composition of the present invention can be used as a pharmaceutical composition, a food composition, a pesticide composition, and a veterinary drug composition, which quickly disintegrates and rapidly foams.
Claims
請 求 の 範 囲 The scope of the claims
固体状の炭酸のアル力リ金属塩(A成分),固体状の脂肪族カルボン酸(B 成分)および活性成分(C成分)を配合して発泡組成物を製造する方法に おいて、 A成分および B成分の一方あるいは両方に C成分を混合し、 両 者をそれぞれ約 0 . 5ないし 5 % (w/w)の水で加湿したのち混合するこ とを特徵とする活性成分含有発泡組成物の製造法。
In the method for producing a foamed composition by blending a solid metal salt of carbonic acid (component A), a solid aliphatic carboxylic acid (component B) and an active component (component C), An active-ingredient-containing foam composition characterized by mixing the C component with one or both of the B component and the B component, humidifying each with about 0.5 to 5% (w / w) water, and then mixing. Manufacturing method.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1985/000050 WO1986004599A1 (en) | 1985-02-07 | 1985-02-07 | Process for producing foaming composition |
JP61009809A JPS61183219A (en) | 1985-02-07 | 1986-01-20 | Method for producing foam composition |
AU52909/86A AU590537B2 (en) | 1985-02-07 | 1986-01-31 | Method for producing foamable compositions |
AT86101330T ATE83652T1 (en) | 1985-02-07 | 1986-02-01 | PROCESS FOR THE MANUFACTURE OF Effervescent Mixtures. |
DE8686101330T DE3687317T2 (en) | 1985-02-07 | 1986-02-01 | METHOD FOR PRODUCING BREWING MIXTURES. |
EP86101330A EP0190689B1 (en) | 1985-02-07 | 1986-02-01 | Method for producing foaming composition |
DK053086A DK169140B1 (en) | 1985-02-07 | 1986-02-04 | Process for the preparation of foaming compositions |
CA000501177A CA1272132A (en) | 1985-02-07 | 1986-02-05 | Method for producing foaming composition |
NZ215054A NZ215054A (en) | 1985-02-07 | 1986-02-05 | Method for producing foaming (effervescent) compositions |
EG63/86A EG17932A (en) | 1985-02-07 | 1986-02-06 | Method for producing foaming composition |
ES551698A ES8800038A1 (en) | 1985-02-07 | 1986-02-06 | Method for producing foaming composition. |
FI860566A FI86799C (en) | 1985-02-07 | 1986-02-07 | Process for making foamable mixtures |
US07/282,989 US4897257A (en) | 1985-02-07 | 1988-12-02 | Method for producing foamable composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1985/000050 WO1986004599A1 (en) | 1985-02-07 | 1985-02-07 | Process for producing foaming composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986004599A1 true WO1986004599A1 (en) | 1986-08-14 |
Family
ID=13846355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1985/000050 WO1986004599A1 (en) | 1985-02-07 | 1985-02-07 | Process for producing foaming composition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1986004599A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5734249B1 (en) * | 1971-04-06 | 1982-07-22 |
-
1985
- 1985-02-07 WO PCT/JP1985/000050 patent/WO1986004599A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5734249B1 (en) * | 1971-04-06 | 1982-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3372053B2 (en) | Chewable or sucking tablets | |
JP2542400B2 (en) | Spray dried acetaminophen | |
ES2236768T3 (en) | COMPRESSED MASTICABLE, IN Dragees, SOLUBLE, CONTAINING RUBBER. | |
US4760094A (en) | Spray dried acetaminophen | |
FI91936B (en) | Method for preparing a solid medicinal product | |
US6296868B1 (en) | Chewable tablets containing mannitol and aspartame | |
US20080181932A1 (en) | Compositions for oral delivery of pharmaceuticals | |
US4093710A (en) | Rapid dissolving effervescent granules | |
IE883583L (en) | Spray dried ibuprofen | |
IE63911B1 (en) | Morphine-containing composition | |
JP2002529496A (en) | Preparation method of oral calcium composition | |
JPS61183219A (en) | Method for producing foam composition | |
US5958445A (en) | Oral Formulations of S(+)-etodolac | |
US4937076A (en) | Chewable aspirin and buffering material tablet and method for producing same | |
CN1315483C (en) | Compositions internal or relevant improvement | |
NO315308B1 (en) | Granulated product or tablet containing an effervescent system and an active pharmaceutical substance, and methods for preparing it | |
EP0415326B1 (en) | Composition for foaming preparation | |
US20040028730A1 (en) | Process for preparing solid dosage forms for unpalatable pharmaceuticals | |
JPS585695B2 (en) | Manufacturing method of effervescent tablets | |
WO1986004599A1 (en) | Process for producing foaming composition | |
JP2004175757A (en) | Medicinal composition | |
JPH04312530A (en) | Method for producing free-flowing, directly compressible vitamins | |
US4515805A (en) | Soluble sodium cromoglycate compositions | |
CN101237850A (en) | Pharmaceutical composition containing indometacin and/or acemetacin | |
WO1987003002A1 (en) | Process for producing foaming composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): MC |